3 Biotech Stocks With Massive Upside to Buy Before August Starts

Biotech is mounting up arsenic 1 of the much absorbing risk-on trades heading into the backmost fractional of 2026. FDA calendars are stacked, obesity Phase 3 readouts are approaching, and aft a mixed archetypal half, the sector's dispersion is wide capable to physique a tiered basket.

Below are 3 names structured by risk: a diversified large-cap compounder, a level communicative with a near-term regulatory catalyst, and a speculative pipeline play trading adjacent a 52-week high.

Regeneron (REGN): The Safest Tier

Regeneron (NASDAQ:REGN) anchors the basket. Shares commercialized astir $687.40 arsenic of July 28, inactive down 11.45% twelvemonth to day contempt a drawstring of quarterly beats. That disconnect is the setup.

In Q1 2026, Regeneron posted gross of $3.605 billion, beating estimates by 3.5% and increasing 19.04% twelvemonth implicit year. Non-GAAP EPS came successful astatine $9.47, up of the $8.90 consensus. Dupixent remains the maturation engine, with planetary income of $4.88 cardinal successful the quarter, up 33%, serving implicit 1.4 cardinal progressive patients worldwide. Libtayo grew 54% and EYLEA HD U.S. income jumped 77%.

The equilibrium expanse is fortress-grade. Regeneron holds $18.54 cardinal successful cash, generated $848 cardinal successful escaped currency travel successful Q1 and authorized a caller $3.0 cardinal stock repurchase programme successful April alongside a $0.94 quarterly dividend. Analyst statement people is $833.31, with 72% bullish sentiment and zero merchantability ratings. The base-case 1-year exemplary people sits astatine $888.57, implying 32.08% upside connected a beta of conscionable 0.236.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Regeneron didn't marque the cut. Grab the names FREE today.

The bull case: Dupixent absorbs the bequest EYLEA decline, near-term catalysts (fianlimab successful metastatic melanoma, garetosmab BLA with an August 2026 enactment date, cemdisiran NDA determination successful Q4 2026) supply aggregate shots connected goal, and the buyback puts a bid nether the stock.

The risk: Legacy EYLEA U.S. income fell 40% successful Q1, and the Samsung EYLEA biosimilar is cleared to motorboat successful January 2027. GAAP gross borderline was trimmed to 77%-78% owed to a Limerick, Ireland manufacturing disruption.